- Home
- ZEPP vs BRNS Comparison
ZEPP vs BRNS Comparison
Compare ZEPP & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$12.04
HOLD
Current Price
$0.54
Company Overview
Basic Information| Metric | ZEPP | BRNS |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.7M | 55.9M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZEPP | BRNS |
|---|---|---|
| Price | $12.04 | $0.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 112.5K | 28.9K |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $778.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.20 | $0.51 |
| 52 Week High | $61.50 | $2.91 |
Technical Indicators
Market Signals| Indicator | ZEPP | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 35.33 | 42.68 |
| Support Level | $10.51 | $0.54 |
| Resistance Level | $15.85 | $0.76 |
| Average True Range (ATR) | 1.28 | 0.05 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 33.30 | 22.62 |
Price Performance
Historical Comparison ZEPP
BRNS
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.